Sign in
Taking people in United StatesPhase 4

Tests tirzepatide for weight loss in young adults with obesity causes

Tests tirzepatide, a weight loss medicine, in young adults with Prader-Willi syndrome or hypothalamic obesity.

Key facts

Who runs it
Grace Kim
Where
Nashville, Saint Paul, and Seattle, United StatesSee the 3 sites
Trial code
Registry title
Tirzepatide in PWS, HO and GNSO
Status
Recruiting
Phase
Phase 4
People taking part
36 people, planned
Started
1 May 2025
Expected to end
Dec 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tirzepatide
Record updated
16 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for young adults aged 18-26 with obesity: people with Prader-Willi syndrome, hypothalamic obesity, or general obesity with no genetic or medical cause. All will get tirzepatide for 1 year.

Age
18 to 26 years
Sex
All sexes can join.
Disease stage
BMI in the obesity range (95th percentile or higher for age and sex, or 30 kg/m2 or higher). Genetically confirmed Prader-Willi syndrome, or hypothalamic obesity diagnosed by a physician, or general obesity unrelated to a genetic syndrome or medical condition.
Earlier treatment
Cannot have used weight loss medication in the last 3 months. Cannot have used any GLP1A or DPP4 inhibitor in the 6 months before screening. Needs a stable care setting, diet and exercise routine for at least 6 months. Cannot have had surgery for obesity.
Biomarker or test result
Genetically confirmed Prader-Willi syndrome for that group. No other marker is asked for.

Main reasons for not taking part

  • Current insulin or sulfonylurea use
  • Weight change of more than 3% in the last 2 months
  • Pregnancy, wish to become pregnant, or breastfeeding
  • Recurrent pancreatitis, chronic kidney disease, gastroparesis, or heart, kidney or liver disease
  • Personal or family history of medullary thyroid carcinoma or MEN syndrome type 2

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) with either 1) genetically confirmed diagnosis of PWS, 2) hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician, 3) general obesity unrelated to a genetic syndrome or underlying medical condition
  • In a stable care setting at least 6 months prior to enrollment
  • Able and willing to participate in study visits including tolerating blood draws, urine samples and tolerate DXA scan
  • Ability to take weekly subcutaneous tirzepatide
  • Consistent caregiver if they are not independent
  • Stable diet and exercise regimen for at least 6 months prior to enrollment
  • Able to use contraceptive methods if able to conceive offspring in order to prevent unintentional pregnancy during the study

Who cannot take part

  • Current or recent (within 3 months of start of study drug initiation) use of weight loss medications
  • Current or prior use of any GLP1A or DPP4 inhibitor during the 6 months before screening
  • Any medications that may affect the study endpoints
  • Significant weight change (>3% weight gain or loss) in the last 2 months prior to enrollment
  • Change in dose of chronic endocrine medications (testosterone, estrogen, levothyroxine, or growth hormone medications) >10%/kg/day for at least 3 months prior to study
  • Cancer within the previous 5 years
  • Previous or planned surgical treatment for obesity
  • History of recurrent pancreatitis, CKD, gastroparesis
  • Chronic/acute heart, kidney, or liver disease
  • Personal or family history of medullary thyroid carcinoma or MEN syndrome type 2
  • Uncontrolled diabetes (A1C >8.5%)
  • Any condition that would prevent successful participation in the study
  • Current use of insulin or sulfonylurea or other medication affecting insulin secretion or GLP1 clearance
  • Current pregnancy or desire to become pregnant within study period, current lactation
  • DVT
  • Current participation in an interventional clinical study
  • Individuals with current substance abuse equivalnt to moderate or severe based on DSM 5 criteria (Hasin DS, 2013)
  • Any suicidal ideation in the past year
  • Unable to perform any of the procedures for the study
  • Have a body weight, height, and/or width that that prohibits the ability to obtain accurate measurements according to the DXA manufacturer's specification

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 26 years old?

Where in United States

  • Vanderbilt University Medical CenterNashville, United StatesContact: Martha UpchurchTaking people
  • Children's MinnesotaSaint Paul, United StatesContact: Diabetes/Endocrinology Research TeamTaking people
  • Seattle Children's HospitalSeattle, United StatesContact: Endocrine Research TeamTaking people

About the trial

What the trial wants to find out

This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.

The 3 groups in the trial

  • Prader-Willi SyndromeExisting treatment, for comparison

    Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) with genetically confirmed Prader-Willi Syndrome between 18-26 years old.

    Treatment: Tirzepatide

  • Hypothalamic ObesityExisting treatment, for comparison

    Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) and hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician.

    Treatment: Tirzepatide

  • General Non-Syndromic ObesityExisting treatment, for comparison

    Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) and general obesity unrelated to a genetic syndrome or underlying medical condition.

    Treatment: Tirzepatide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effects of Tirzepatide in Young Adults With Prader-Willi Syndrome, Hypothalamic Obesity and General Non-Syndromic Obesity
Plain-language title
Tests tirzepatide for weight loss in young adults with obesity causesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06901245, who can take part
Record updated
16 September 2025